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COST-BENEFIT ANALYSIS OF OSELTAMIVIR VERSUS NO ANTIVIRAL TREATMENT FROM THE EMPLOYER PERSPECTIVE:THE ROCHE BRAZIL CASE
Moreno
. A one-year timeframe was used for the comparison. A total of 73 influenza cases were observed during the year of 2006 at Roche Brazil. Direct medical costs were obtained from the HMO responsible for Roche employees. Indirect costs related to absenteeism were based on a human capital approach considering the company expenses with personnel (salary + fringe benefits) as the workday value for each worker. Discounting was not included due to the short-term perspective of the analysis. RESULTS: Total costs were R$ 20,198 for oseltamivir treatment group, and for the no antiviral treatment group total costs ranged from R$ 41,062 to R$ 55,261 depending on the study utilized. The cost-savings observed for oseltamivir were due to lower absenteeism costs (diference between the two groups ranged from from R$ 26,842 to R$ 41,040) and its less frequent disease complications. Multi-way Sensitivity analyses confirmed the robustness of the results obtained. CONCLUSION: The analysis suggests that providing oseltamivir would incur in a substantial benefit for the employer. It worth to remind that the size of the benefit is also related to the company's health care program (e.g. vaccination coverage).
PIN5 COST-EFFECTIVENESS OF TIGECYLINE IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN GERMANY
Kuchenbecker U 1 , Runge C 1 , Krueger WA 2 1 Wyeth Pharma, Muenster, Germany, 2 Eberhard-Karls-University, Tuebingen, Germany OBJECTIVES: Increasing rates of resistance to antimicrobial therapy increase the risk of therapeutic failure and impose a challenge on therapy of infections. Thereby, resistant microorganisms lead to a significant increase in patient morbidity, mortality, and health care costs. Tigecycline, a glycylcycline, offers a broad-spectrum of activity including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). In order to assess the cost-effectiveness of Tigecycline vs. selected standard antibiotics, we modeled its use in the treatment of complicated intra-abdominal infections (cIAI). METHODS: A decisionanalytic model was developed and adapted to estimate expected outcomes and costs of initial antibiotic therapy. Tigecycline therapy was compared with ceftriaxone/metronidazole, ciprofloxacin/metronidazole, imipenem/cilastatin and levofloxacin/ metronidazole. We used published data on pathogen prevalence, in-vitro eradication rates, length of stay (LOS), failure rates and mortality in order to populate the model. Information on inpatient costs and drug costs were derived from official databases. RESULTS: Overall success rate of initial tigecycline therapy was 89%. Ceftriaxone/metronidazole (71%), ciprofloxacin/ metronidazole (70%), imipenem (82%), levofloxacin/ metronidazol (76%) showed lower suc-cess rates. LOS was shortest with tigecycline therapy (13.8 d vs. 15.1, 15.1, 14.3, 14.7 respectively) . Cost-effectiveness of tigecycline was better than for all comparators (6631.76€ vs. 8542.42€, 9200.67€, 7251.55€ and 7925.48€ per treatment success). Tigecycline therapy was dominant, e.g. it was more ef-fective than all other regimens at lower total costs. CONCLUSION: The model indicates that empirical therapy with tigecycline is more cost-effective than standard antibiotic regimens.
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